Written and peer-reviewed by physicians—but use at your own risk. Read our disclaimer.

amboss

Trusted medical answers—in seconds.

Get access to 1,000+ medical articles with instant search
and clinical tools.

Try free for 5 days

Antipsychotics

Last updated: March 4, 2021

Summary

Antipsychotics are a heterogeneous group of substances used primarily to treat schizophrenia, psychosis, mania, delusions, and states of agitation. The term neuroleptics was formerly used interchangeably with antipsychotics because early antipsychotic drugs induced apathy, quiescence, and reduced psychomotor activity, but newer antipsychotic drugs no longer have these effects. The antipsychotic effect of first-generation antipsychotics (also called typical antipsychotics, e.g., haloperidol) is based on D₂ antagonism, while second-generation antipsychotics (also called atypical antipsychotics) interact with several receptors (e.g., D₂, D₃, D₄, 5-HT). Extrapyramidal symptoms, which include acute dystonia, akathisia, and tardive dyskinesia, are the most common side effects of first-generation antipsychotics. Metabolic side effects (e.g., weight gain, insulin resistance), on the other hand, are more typical of second-generation antipsychotics. A potentially life-threatening side effect of both first-generation and second-generation antipsychotics is neuroleptic malignant syndrome, which manifests with fever, muscle rigidity, autonomic instability, and mental status changes.

Overview

Description

First-generation antipsychotics (also called typical antipsychotics): block D2 receptor → ↑ cAMP
- High-potency antipsychotics have a strong antipsychotic effect even at relatively low doses, but they also more commonly cause neurologic side effects (e.g., extrapyramidal symptoms) than low-potency antipsychotics.
- Low-potency antipsychotics more commonly cause anticholinergic, antihistamine, and sympathetic α₁-blockade effects.
- Stored in fat tissue (lipid soluble) and, therefore, only slowly eliminated from the body.
Second-generation antipsychotics: (also called atypical antipsychotics): most are 5-HT₂ and D₂ antagonists with varying α and H₁ receptor effects

Overview of antipsychotics
			Mechanism of action	Indications	Side effects
First-generation antipsychotics (FGAs)	High-potency antipsychotics	Haloperidol Fluphenazine Perphenazine Trifluoperazine Pimozide	Dopamine-specific antagonism (D₂ receptor)	Schizophrenia Bipolar disorder Acute psychosis Delirium Acute agitated states (e.g., patients who are agitated and aggressive due to alcohol and/or illicit drug use) Tourette syndrome OCD (concomitant therapy) Huntington disease	Hyperprolactinemia Extrapyramidal symptoms most common in high-potency FGAs Prolonged QT interval Neuroleptic malignant syndrome Metabolic and anticholinergic effects less pronounced
First-generation antipsychotics (FGAs)	Low-potency antipsychotics	Chlorpromazine Thioridazine	Dopamine antagonism Anticholinergic Antihistaminergic (primarily sedative)	Acute agitation Delirium	Anticholinergic effects, sympatholytic effects, metabolic effects, and sedation dominate EPS less common
Second-generation antipsychotics (SGAs)		Clozapine Olanzapine Risperidone Quetiapine Amisulpride Ziprasidone Aripiprazole Lurasidone Asenapine Iloperidone Paliperidone	D₂ receptor antagonism (less pronounced than that of FGAs) 5-HT₂A receptor antagonism Interaction with several other receptors (i.e., D₃, D₄, α-adrenergic, and H₁ receptors) Aripiprazole is a partial D₂ agonist	Schizophrenia Bipolar disorder Acute psychosis Postpartum psychosis MDD with psychotic features OCD (concomitant medication) Tourette syndrome Anxiety disorders Huntington disease	Metabolic effects (usually weight gain, hyperglycemia, dyslipidemia) most prominent Prolonged QT interval ^[1] Hyperprolactinemia (less pronounced than in FGAs) Neuroleptic malignant syndrome Clozapine can cause agranulocytosis and lowers the seizure threshold ^[2] Sedation, somnolence EPS less common Anticholinergic and sympatholytic effects

HAL TRIed to FLy high: HALoperidol, TRIfluoperazine, and FLuphenazine are high potency antipsychotics.

CHarlatanes and THIeves are lowlifes: CHlorpromazine and THIoridazine are low potency antipsychotics.

Indications

All antipsychotics, except for clozapine (used for treatment-resistant schizophrenia), have similar clinical effectiveness.
The choice of drug depends on the side effect profile of the antipsychotic drugs and the patient's clinical status.
SGAs are preferred in many cases because they carry a lower risk of EPS; however, in some patients (e.g., those with significant metabolic risk factors), FGAs may be more suitable.

Overview of indications
	Important indications	Preferred agents
Acute therapy	Acute psychosis	First-line: SGAs (e.g., aripiprazole for acute delusions; risperidone for acute mania or hypomania) Alternative: high-potency antipsychotics (e.g., haloperidol)
	Bipolar affective disorder or acute mania
	Delirium	High-potency antipsychotics (alternatively, low-potency antipsychotics)
	Delusional or agitated states (e.g., patients who are agitated and aggressive due to alcohol and/or illicit drug use)	High-potency antipsychotics Children and adolescents: risperidone Elderly: risperidone or melperone
	Psychotic symptoms caused by medication for Parkinson disease (dopamine agonists)	Clozapine
	Psychosis during pregnancy	First-line: FGAs (e.g., haloperidol)
	Postpartum psychosis	First-line: SGAs (e.g., quetiapine, risperidone, olanzapine)
	Dementia (should be reserved for severe symptoms only)	Risperidone
Long-term therapy	Schizophrenia and other chronic psychotic disorders	SGAs (effective for positive and negative symptoms) In cases of treatment failure Switch to high-potency antipsychotics (primarily effective for positive symptoms). Or clozapine
	Concomitant medication for patients with obsessive-compulsive disorders	SGAs
	Treatment-resistant schizophrenia and schizophrenia associated with persistent suicidality	Clozapine
	Tic disorders, Tourette syndrome Huntington disease	Tiapride

To reduce/avoid anticholinergic side effects in patients of advanced age, high-potency substances (e.g., haloperidol, risperidone) or melperone are preferred.

Adverse effects

Overview of adverse effects
		Characteristics	First-generation antipsychotics	Second-generation antipsychotics
Extrapyramidal symptoms (EPS)		See “Extrapyramidal symptoms.”	High-potency FGAs have the highest incidence of EPS. Low-potency FGAs have a rate of EPS similar to that of SGA.	Significantly fewer motor side effects (EPS) due to reduced D₂ receptor antagonism; greater affinity for 5HT_2A receptors and interaction with other receptors
Hyperprolactinemia		Elevated prolactin levels: Dopamine inhibits the release of prolactin via the D₂ receptor in the tuberoinfundibular pathway. Therefore, dopamine antagonists increase the effects of prolactin. In men: gynecomastia, galactorrhea, hypogonadotropic hypogonadism (erectile dysfunction, reduced libido, infertility) In women: galactorrhea, oligomenorrhea, hypogonadotropic hypogonadism (amenorrhea, reduced libido, infertility)	All FGAs cause elevated prolactin levels. Annual monitoring of symptoms is recommended.	Smaller increase in prolactin levels compared to typical antipsychotics Most common in risperidone, amisulpride, and paliperidone
Cardiac adverse effects	Prolonged QT interval	Potassium channel-mediated effect Can lead to life-threatening arrhythmias (torsades de pointes and ventricular fibrillation)	All FGAs Most common in intravenous haloperidol and thioridazine	All SGAs (particularly iloperidone, ziprasidone)
Cardiac adverse effects	Other	Myocarditis Cardiomyopathy Sinus tachycardia	Not reported	Clozapine
Anticholinergic adverse effects		Dry mouth Constipation Blurred vision, mydriasis Urinary retention Tachycardia	More common in low-potency FGAs than in SGAs Mild in high-potency FGAs	Uncommon in most agents Clozapine, olanzapine, and quetiapine have the highest incidence of anticholinergic effects. Clozapine commonly causes sialorrhea.
Metabolic adverse effects		Usually weight gain, hyperglycemia, dyslipidemia Occasionally loss of appetite and weight loss	More common in low-potency FGAs	Prominent in most SGA Clozapine, olanzapine, and quetiapine carry the highest risk of metabolic syndrome (hyperglycemia, dyslipidemia, weight gain). Olanzapine: asymptomatic increase of liver enzymes.
Sympatholytic adverse effect		Orthostatic hypotension (due to α₁-adrenergic blockade)	More common in low-potency FGAs Rare in high-potency FGAs	Common during treatment initiation and dose adjustments Particularly olanzapine
Sedation		Mediated via histamine H₁ receptor antagonism	Prominent in low-potency FGAs	All SGAs (tolerance usually develops within a few days of treatment) Quetiapine is often used as a sleep aid in low doses.
Hematologic		Agranulocytosis (usually within the first 4 months of therapy)	Extremely rare	Clozapine carries a high risk of agranulocytosis (usually within the first 4 months of therapy).
Ocular effects		Lenticular and corneal deposits (especially chlorpromazine) Cataracts Epithelial keratopathy Retinitis pigmentosa (especially thioridazine)	Associated with low-potency FGAs Chlorpromazine Thioridazine carries the highest risk of retinitis pigmentosa.	Not reported
Thermoregulation		Hyperthermia or hypothermia	Associated with phenothiazines (e.g., fluphenazine) ^[3] Patients receiving these medications should avoid extreme temperatures. ^[4]	Most commonly associated olanzapine and risperidone
Neuroleptic malignant syndrome		Life-threatening side effect See “Neuroleptic malignant syndrome.”	All antipsychotics

Chlorpromazine causes Corneal deposits; Thioridazine causes reTinal deposits.

cRISPy PINEapple chips will make you fat: olanzaPINE/clozaPINE and RISPeridone cause weight gain.
When administering CLOzapine, check the bone marrow CLOsely due to risk of agranlocytosis.

Extrapyramidal symptoms (EPS)

Definition: : a collection of movement disorders that are typically due to disruption of dopaminergic pathways in the basal ganglia, resulting in bradykinesia, rigidity, dystonia, athetosis, chorea, ballismus, akathisia, tics, and tremors
Etiology
- All antipsychotics that interact with the D₂ receptor may cause EPS, but the probability of this side effect is significantly higher with high-potency (typical) antipsychotics than with SGAs
- Metoclopramide, although not an antipsychotic, may also cause extrapyramidal symptoms.
- Anticonvulsants (e.g., carbamazepine)
Pathophysiology: Inhibition of the nigrostriatal dopaminergic pathways results in EPS.
- First-generation high-potency antipsychotics: D₂antagonism → EPS
- Second-generation antipsychotics: weaker D₂antagonism → fewer EPS

Overview of extrapyramidal symptoms
EPS subtype	Onset	Symptoms	Treatment
Acute dystonia (also see “Dystonia”) ^[5]	Hours to days	Painful and lasting muscle spasms and stiffness predominantly affecting the head, neck, and tongue Facial grimacing, torticollis Tongue protrusion or twisting Oculogyric crisis (upward deviation of the eyes) In severe cases: laryngospasm, opisthotonus of the back	Acute treatment: anticholinergics or antihistamines ^[6] First-line: benztropine Alternatives Diphenhydramine Benzodiazepines (e.g., diazepam) Switch to an antipsychotic drug with lower risk of EPS (SGA) or begin secondary prophylaxis with benztropine Prophylaxis using benztropine or diphenhydramine is recommended for patients who receive intramuscular haloperidol (especially individuals with little prior exposure to FGA). Intubation in case of laryngospasm
Pseudoparkinsonism	Week 1	Cogwheel rigidity, stiff gait, tremor Bradykinesia	Dose reduction or switch to an antipsychotic drug with lower risk of EPS (SGA) Anticholinergic (e.g., benztropine) or a dopamine agonist (e.g., amantadine)
Akathisia	Weeks 1–8	Restlessness/compelling urge to move Inability to sit or stand still	Dose reduction or switch to an antipsychotic drug with lower risk of EPS (SGA) First-line: beta blocker such as propranolol Alternative Benztropine Benzodiazepines
Tardive dyskinesia	Months–years	Involuntary movements of the mouth and tongue; limbs, face, and respiratory muscles caused by chronic use of antipsychotic drugs Repetitive chewing and lip smacking Choreic movements	First-line: discontinuation of antipsychotic drug Switch to SGA (less EPS, especially clozapine and quetiapine) Anticholinergics or antipsychotic dose reduction may initially worsen the condition. Second-line: VMAT inhibitors Valbenazine and deutetrabenazine ^[7] Tetrabenazine (more side effects, e.g., aggravation of depressive symptoms)

ADAPT: extrapyramidal symptoms include Acute Dystonia, Akathisia, Parkinsonism, and Tardive dyskinesia.

Neuroleptic malignant syndrome (NMS) ^[8]^[9]^[10]

Description: life-threatening neurological disorder usually associated with antipsychotics; that is characterized by a tetrad of features (fever, muscle rigidity, autonomic instability, and mental status changes) as well as rhabdomyolysis and elevated creatine kinase
Etiology
- Reaction to antipsychotic drugs (more common with high-potency FGAs than with SGAs)
- Agents that affect the CNS (e.g., carbamazepine, lithium, venlafaxine)
- Certain antiemetics (e.g., metoclopramide, promethazine)
- Genetic predisposition
- A connection between NMS and the duration of therapy or therapeutic dose has not been established.
Pathophysiology: The underlying mechanism is not well understood; disruption of numerous neurotransmitter pathways is suspected.
- Central D₂ receptor blockade in the nigrostriatal pathway and hypothalamus, resulting in movement disorders and impaired thermoregulation
- Increased sympathetic tone disrupts autonomic regulation and increases muscle tone and metabolism.
- Increased release of calcium from the SR of striated muscle cells, resulting in increased contractility and muscle breakdown
Clinical features: Onset usually occurs within 2 weeks of the first dose.
- Muscle rigidity (lead-pipe rigidity), akinesia, tremor
- Autonomic instability
  - Hyperthermia
  - Tachycardia, dysrhythmias, labile blood pressure
  - Tachypnea
  - Diaphoresis
- Mental status change (encephalopathy)
  - Confusion
  - Delirium
  - Reduced vigilance
  - Stupor
Diagnostics
- ↑↑ Creatine kinase
- Leukocytosis
- ↑ Transaminases
- Metabolic acidosis
- Myoglobinuria
- Electrolyte abnormalities (hypocalcemia, hyperkalemia, hyponatremia or hypernatremia)
- Low serum iron concentration
Differential diagnosis
- Lethal catatonia )
- See “Differential diagnosis of drug-induced hyperthermia.”
Treatment
- Discontinuation of the antipsychotic drug
- Supportive measures (e.g., ICU care)
- Pharmacotherapy
  - Dantrolene
  - Alternatives: bromocriptine, apomorphine, or amantadine
  - Benzodiazepines can be administered to treat psychomotor agitation.

Learn Neuroleptic Malignant Syndrome Faster with Picmonic (NCLEX® and USMLE, Step 1, Step 2 CK)

To remember the different symptoms of neuroleptic malignant syndrome, think FALTER: Fever, Autonomic instability, Leukocytosis, Tremor, Elevated enzymes (creatine kinase, transaminases), Rigor

We list the most important adverse effects. The selection is not exhaustive.

References

Polcwiartek C, Sneider B, Graff C, et al. The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach. Psychopharmacology (Berl). 2015; 232 (18): p.3297-3308. doi: 10.1007/s00213-015-4024-9 . | Open in Read by QxMD
Jason Wong, Nicholas Delva. Clozapine-Induced Seizures: Recognition and Treatment. The Canadian Journal of Psychiatry. 2007; 52 (7): p.457-463. doi: 10.1177/070674370705200708 . | Open in Read by QxMD
Fluphenazine. https://pubchem.ncbi.nlm.nih.gov/compound/fluphenazine#section=Top. . Accessed: May 18, 2017.
Zonnenberg C, Bueno-de-Mesquita JM, Ramlal D, Blom JD. Hypothermia due to Antipsychotic Medication: A Systematic Review. Front Psychiatry. 2017; 8 . doi: 10.3389/fpsyt.2017.00165 . | Open in Read by QxMD
Life in the fast lane - Acute Dystonic Reaction (Stiff and Twisted). https://lifeinthefastlane.com/toxicology-conundrum-030/. Updated: April 20, 2010. Accessed: May 18, 2017.
Cloud LJ, Jinnah HA. Treatment strategies for dystonia. Expert Opin Pharmacother. 2010; 11 (1): p.5-15. doi: 10.1517/14656560903426171 . | Open in Read by QxMD
Uhlyar S, Rey JA. Valbenazine (Ingrezza): The First FDA-Approved Treatment for Tardive Dyskinesia.. P T. 2018; 43 (6): p.328-331.
Perry PJ, Wilborn CA. Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management.. Ann Clin Psychiatry. 2012; 24 (2): p.155-162.
Sahoo MK, Agarwal S, Biswas H. Catatonia versus neuroleptic malignant syndrome: the diagnostic dilemma and treatment. Ind Psychiatry J. 2014; 23 (2): p.163-165. doi: 10.4103/0972-6748.151703 . | Open in Read by QxMD
Lang F, Lang S, Becker T, Jäger M. Neuroleptic malignant syndrome or catatonia? Trying to solve the catatonic dilemma. Psychopharmacology. 2015; 232 (1): p.1.